Core Viewpoint - The company is facing significant operational challenges, including frozen bank accounts and potential changes in control due to legal disputes involving its major shareholder [2][3][16]. Group 1: Legal and Financial Issues - Deyou Holdings Limited is involved in an arbitration case with Ms. Chen Hua, resulting in a court ruling that may lead to the auction of 14,000,000 shares, representing 54.69% of Deyou Holdings' total shares and 6.98% of the company's total equity [2][16]. - The company disclosed that its wholly-owned subsidiary, Sichuan Zhongshu Shilian Construction Engineering Co., Ltd., had its main bank accounts frozen due to a contractual dispute, affecting 99.49% of its cash balance [3][10]. - The company has been under continuous risk warnings due to negative net profits over the last three fiscal years, with the latest audited net profit for 2024 reported at -27,303,694.80 yuan [4][9][17]. Group 2: Operational Performance - The company has struggled with production and operational activities since December 2018, leading to a significant decline in market orders and ongoing production halts [5][11]. - In 2023, the company achieved a revenue of 368,402,027.39 yuan but reported a net loss of -8,582,265.60 yuan, indicating ongoing financial difficulties [12][13]. - The company is attempting to pivot towards renewable energy projects, with signed contracts in 2024 totaling 38,511,168.67 yuan for EPC engineering and 42,251,262.72 yuan for equipment sales, although the overall business scale has decreased [13].

Core Viewpoint - Jiangxi Mubang High-tech Co., Ltd. has experienced abnormal stock trading fluctuations, with a cumulative closing price deviation of 12% over three consecutive trading days, leading to regulatory scrutiny and potential delisting risks [1][3]. Group 1: Stock Trading Fluctuations - The company's A-share stock has seen a cumulative closing price deviation of 12% over three consecutive trading days, qualifying as abnormal trading activity according to Shanghai Stock Exchange regulations [1]. - The company has conducted a self-examination and confirmed that there are no undisclosed significant information affecting the stock price, aside from what has already been disclosed [1][5]. Group 2: Financial Performance and Risks - The 2024 annual report revealed a negative net profit, with operating revenue below 300 million yuan after excluding non-core business income, resulting in a delisting risk warning effective May 6, 2025 [1][2]. - The company has received a negative opinion in its internal control audit report for 2024, leading to additional risk warnings [2]. - Legal issues have led to the freezing of bank accounts totaling approximately 27.75 million yuan, including 26.86 million yuan from the fundraising account, which may impact project implementation [2][3]. Group 3: Regulatory Actions - The company has been notified of an investigation by the China Securities Regulatory Commission (CSRC) due to suspected false disclosures in financial reports [3][7]. - As of June 2025, non-operating fund occupation by the controlling shareholder and related parties reached 81.32 million yuan, exceeding 5% of the company's latest audited net assets, which may lead to further regulatory actions if not resolved within one month [2][6]. Group 4: Corporate Governance - The board of directors has confirmed that there are no undisclosed matters that should have been reported according to the Shanghai Stock Exchange regulations, and previous disclosures do not require correction or supplementation [8].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600365 证券简称：ST通葡 公告编号：临2025-038 通化葡萄酒股份有限公司 关于股票被实施其他风险警示相关事项的进展公告 2021年4月30日，公司披露了《ST通葡关于违规担保自查公告》（公告编号：临2021-044），公司披露 了截至2021年4月29日相关公司违规担保的解决进展及影响。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 2021年8月31日，公司披露了《通化葡萄酒股份有限公司关于违规担保事项解除进展公告》（公告编 号：临2021-077），公司对相关公司的相关担保、还款等责任已经解除。 重要内容提示： ● 通化葡萄酒股份有限公司（以下简称"公司"）因触及《上海证券交易所股票上市规则》（2019年4月 修订）13.4.1第（五）项规定，公司股票被实施 "其他风险警示"。 ● 根据《上海证券交易所股票上市规则》（2025年4月修订）第9.8.4条规定，公司将每月披露一次其他 风险警示相关事项的进展情况，提示相关风险。 一、公司被实施其他风险警 ...

*ST信通（600289）公告，公司撤销退市风险警示和部分其他风险警示，并于2025年7月9日起复牌。公 司2024年实现营业收入3.2亿元，归属于母公司所有者的净利润为-9670.78万元，扣除非经常性损益后的 净利润为-5447.57万元，归属于上市公司股东的净资产为6.26亿元。公司剩余需承担赔偿责任的违规担 保案件涉案本金合计为6.06亿元。公司股票简称变更为"ST信通"，股票代码"600289"保持不变，股票交 易价格的日涨跌幅限制仍为5%。 ...

Core Viewpoint - Unimed Pharmaceutical is facing significant operational challenges due to the suspension of its core subsidiary, Tianjin Unimed Biopharmaceutical Co., Ltd, which is expected to impact 60% of the company's revenue [5][6][12]. Group 1: Company Operations - Tianjin Unimed has been suspended from production and sales since April 22, 2024, due to non-compliance with drug production quality management standards [6][9]. - The expected recovery timeline for Tianjin Unimed's operations has been extended, with a new estimate indicating that normal production will not resume until July 21, 2025 [8]. - The suspension has triggered a chain reaction in the procurement market, with several regions halting purchases of interferon products produced by Tianjin Unimed [9]. Group 2: Financial Impact - In 2024, Tianjin Unimed generated revenue of 217 million yuan, accounting for 60.09% of Unimed Pharmaceutical's total revenue and 9.8% of its consolidated net profit [6]. - Unimed Pharmaceutical has reported continuous losses over the past three years, with net profits of -14.68 million yuan in 2022, -332 million yuan in 2023, and -137 million yuan in 2024 [12]. - The company's first-quarter performance in 2024 showed a revenue decline of 57.84% year-on-year, with a net profit of -36.85 million yuan, down 33.01% [12]. Group 3: Regulatory and Compliance Issues - Unimed Pharmaceutical has faced long-standing internal control risks, including failure to disclose related party transactions and inaccurate earnings forecasts [11]. - The company has been penalized by the China Securities Regulatory Commission for various compliance failures, resulting in fines and a 10-year market ban for its former chairman [11].

Core Viewpoint - The company, Shenzhen Yushun Electronics Co., Ltd., has shown improvement in its financial performance and operational stability, addressing previous concerns regarding its ability to continue as a going concern. The company has reported significant revenue growth and has taken strategic actions to enhance its business structure and profitability [2][6][21]. Financial Performance - In 2023, the company reported a net profit attributable to shareholders of 964,400 RMB, while the net profit after deducting non-recurring gains and losses was -18,478,000 RMB, indicating a cumulative loss of 1,753,521,000 RMB over the years [8][12]. - The total operating revenue for 2023 was 155,191,700 RMB, with main business revenue of 150,334,100 RMB, reflecting a small scale of operations and negative cash flow from operating activities [8][12]. - For 2024, the company achieved an operating revenue of 220,282,400 RMB, a 41.94% increase compared to 2023, and reported a first-quarter revenue of 45,727,400 RMB in 2025, a 93.73% year-on-year growth [8][19]. Operational Developments - The company has successfully eliminated major uncertainties regarding its ability to continue operations, as evidenced by improved financial metrics and operational stability [19][21]. - The company has made strategic acquisitions, including a 75% stake in Shanghai Fubang Industrial Co., Ltd., which contributed an additional 99,145,700 RMB in revenue and 14,514,400 RMB in net profit to the consolidated financial statements in 2024 [11][19]. - The company has focused on enhancing its product offerings and expanding into new markets, particularly in the automotive sector, which has shown promising growth potential [10][11]. Risk Management - The company has addressed previous risk warnings related to its stock trading by demonstrating improved financial health and operational performance, leading to the removal of risk warnings associated with its stock [6][18]. - The company has maintained a reasonable financial structure, with a debt-to-asset ratio of 44.83% and a current ratio of 1.28, indicating a stable financial position [13][19]. - The management has implemented measures to ensure liquidity and operational continuity, including financial support from its controlling shareholder [15][21].

Core Viewpoint - Guizhou BaiLing Pharmaceutical Group Co., Ltd. has addressed the issues raised in the 2023 internal control audit report, and the impact of the negative opinion has been eliminated, allowing the company to meet the conditions for the removal of risk warnings on its stock [3][4][6]. Group 1: Internal Control Audit Findings - The 2023 internal control audit report indicated significant deficiencies in the company's internal controls related to sales expenses, including delays in expense recognition and incomplete confirmations [6][9]. - The company has implemented a series of corrective measures to enhance internal controls and ensure compliance with relevant regulations [6][8]. Group 2: Compliance and Rectification Measures - The company has established a compliance management department and engaged third-party consulting firms to optimize internal controls and rectify deficiencies [7][8]. - Continuous training for relevant personnel has been emphasized to strengthen governance and prevent violations [8]. Group 3: Current Status and Future Outlook - As of December 31, 2024, the company maintained effective internal controls over financial reporting in all material respects [4][6]. - The company has confirmed that it does not meet any conditions that would require additional risk warnings under the Shenzhen Stock Exchange listing rules [5][6].

Core Viewpoint - The legal opinion letter from Shanghai Jintiancheng (Fuzhou) Law Firm addresses the inquiries from the Shenzhen Stock Exchange regarding the 2024 annual report of Helitai Technology Co., Ltd, focusing on the company's debt restructuring and compliance with relevant regulations [1][2][3]. Group 1: Debt Restructuring and Financial Performance - The company confirmed a debt restructuring gain of 4.803 billion yuan and a debt restructuring default expense of 904 million yuan during the reporting period, with a net asset balance of 1.856 billion yuan at the end of the reporting period [4]. - The company achieved a net profit of 1.519 billion yuan, marking a turnaround from losses, primarily due to debt restructuring and asset divestiture [12]. - The company reported a significant decrease in operating income by 71.35%, attributed to business segment reductions and loss of clients due to long-term funding shortages [12]. Group 2: Compliance with Stock Exchange Regulations - The company has met the conditions to apply for the removal of the delisting risk warning, as it no longer meets the criteria for delisting under the Shenzhen Stock Exchange's regulations [12][24]. - The company’s net assets were confirmed to be positive at 1.856 billion yuan for the 2024 fiscal year, eliminating the previous negative net asset situation [12][20]. - The company has disclosed its internal control audit report, which received a standard unqualified opinion, fulfilling the disclosure requirements [12][20]. Group 3: Legal and Audit Matters - The company is involved in 645 litigation and arbitration cases, with a total amount in dispute of approximately 6.004 billion yuan, representing 323.55% of the company's latest audited net assets [24][25]. - The company has confirmed other payables of 3.2378 million yuan based on the requirements of relevant accounting standards [24]. - The audit procedures regarding the company's litigation and arbitration situations have been executed, with the audit firm providing clear opinions on the matters [24].

证券代码：300152 证券简称：ST 新动力 公告编号：2025-037 雄安新动力科技股份有限公司 关于公司股票交易被实施其他风险警示暨可能被实施退市风险警示 相关事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、公司被实施其他风险警示暨可能被实施退市风险警示的相关情况 雄安新动力科技股份有限公司(以下简称"公司或新动力")2024 年度财务 报告内部控制被中兴财光华会计师事务所（特殊普通合伙）出具了否定意见的审 计报告。根据现行《深圳证券交易所创业板股票上市规则》第 9.4 条第（四）项 规定，公司出现"（四）最近一个会计年度财务报告内部控制被出具无法表示意 见或者否定意见的审计报告，或者未按照规定披露财务报告内部控制审计报告" 的情形，公司股票交易被深圳证券交易所实施其他风险警示；根据《深圳证券交 易所创业板股票上市规则》第 10.4.4 条第（五）项规定，上市公司出现"首个 会计年度财务报告内部控制被出具无法表示意见或者否定意见的审计报告，或者 未按照规定披露财务报告内部控制审计报告"的情形，上市公司应当立即披露股 票交易可能被实施 ...

Core Viewpoint - Jiangsu Huasheng Tianlong Optoelectronic Equipment Co., Ltd. is facing significant operational challenges, including the freezing of major bank accounts and potential changes in control due to judicial actions against its major shareholder [1][5][12] Group 1: Financial Performance - The company reported a net profit of -27,073,025.26 yuan for the 2024 fiscal year, with an audit opinion indicating significant uncertainty regarding its ability to continue as a going concern [5][12] - The net profit for 2023 was -8,582,265.60 yuan, and for 2022, it was -15,998,642.96 yuan, indicating a trend of negative profitability over the past three years [7][8] - The company’s net assets were reported as negative for the 2024 fiscal year, triggering a delisting risk warning according to the Shenzhen Stock Exchange rules [12] Group 2: Operational Challenges - The company has been unable to secure market orders for its single crystal and multi-crystal furnace products since December 2018, leading to severe operational difficulties [1][2] - As of December 13, 2023, four out of seven bank accounts of its wholly-owned subsidiary, Sichuan Zhongshu, were frozen, with a total frozen amount of 1,026.03 million yuan, representing 99.49% of its cash balance [5][6] - The freezing of bank accounts is primarily due to legal disputes, which have significantly impacted the company's ability to conduct its business operations [6][11] Group 3: Shareholder and Control Issues - Major shareholder Dayou Holdings' 14,000,000 shares are subject to judicial auction, which could lead to a change in control of the company [1][12] - Dayou Holdings currently holds 6.98% of the total shares, and the risk of judicial disposal of these shares remains, potentially affecting the company's governance [1][12] - The company is actively seeking to resolve the issues related to the freezing of bank accounts and the potential impact on its operations and shareholder structure [6][11]